China NT Pharma Group Company Limited (NT Pharma) filed its Monthly Return for Equity Issuer with Hong Kong Exchanges and Clearing on 01 June 2026, detailing equity movements for the month ended 31 May 2026.

Authorised / Registered Capital • Ordinary shares: 62.59 billion authorised at a par value of USD 0.0000008, representing USD 50,074 in authorised capital. • Preference shares: 32.50 million authorised at the same par value, equivalent to USD 26 in authorised capital. Total authorised share capital stood at USD 50,100, unchanged from April.

Issued Share Position • Ordinary shares in issue (excluding treasury shares) remained at 948.99 million. • No treasury shares were held or cancelled, and no new shares were issued during the month. • Consequently, total issued share capital was stable at 948.99 million shares.

Compliance and Corporate Actions • NT Pharma confirmed full compliance with the Main Board’s minimum public-float requirement of 25%. • The company reported no movements in share options, warrants, convertibles, other equity-linked instruments or treasury-share transactions for the period.

The filing, signed by Executive Director Ng Tit, indicates a month of capital stability with no dilution or corporate actions affecting shareholders as at 31 May 2026.